|
PCMTD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66067160023431E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.90558721316847E-14 |
| Normal-vs-Stage2 |
5.99969999999228E-05 |
| Normal-vs-Stage3 |
2.99760216648792E-15 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
1.376400E-02 |
| Stage1-vs-Stage3 |
9.693800E-02 |
| Stage1-vs-Stage4 |
8.2736999995614E-07 |
| Stage2-vs-Stage3 |
2.437100E-03 |
| Stage2-vs-Stage4 |
2.2446999999981E-05 |
| Stage3-vs-Stage4 |
2.251900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62925228863742E-12 |
| Normal-vs-AfricanAmerican |
6.37700003913722E-09 |
| Normal-vs-Asian |
1.6286971771251E-12 |
| Caucasian-vs-AfricanAmerican |
9.794800E-01 |
| Caucasian-vs-Asian |
5.356000E-01 |
| AfricanAmerican-vs-Asian |
6.857400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66422431391311E-12 |
| Normal-vs-Female |
4.76285677564192E-14 |
| Male-vs-Female |
7.809000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63935531816151E-12 |
| Normal-vs-Age(41-60Yrs) |
3.10862446895044E-14 |
| Normal-vs-Age(61-80Yrs) |
3.57791574145949E-12 |
| Normal-vs-Age(81-100Yrs) |
2.408500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.915000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.718600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.453600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.738000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.321200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.071000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.151100E-04 |
| Classical-VS-Follicular |
3.51659999997533E-06 |
| Classical-VS-Other |
7.880400E-01 |
| Classical-VS-Normal |
1.64557256709941E-12 |
| Tall-VS-Follicular |
2.5142999904304E-09 |
| Tall-VS-Other |
1.968640E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.045200E-01 |
| Follicular-VS-Normal |
4.4326000000483E-06 |
| Other-VS-Normal |
6.767100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
6.29650000000259E-05 |
|
|
